Abstract
Objective: To review management of papillary thyroid cancer. Methods: Review of the literature. Results: Papillary thyroid cancer is the most common endocrine malignancy. The standard treatment for papillary thyroid cancer is thyroidectomy. Adjuvant therapy includes lifelong thyroid-stimulating hormone suppression and radioiodine therapy. Local recurrence is common and is normally treated with surgery and/or radioiodine. Metastatic radioiodine-resistant disease is a more infrequent event. Conclusion: The incidence of papillary thyroid cancer is rapidly increasing. Surgery remains the cornerstone of treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 233-240 |
| Number of pages | 8 |
| Journal | Journal of Clinical Outcomes Management |
| Volume | 21 |
| Issue number | 5 |
| State | Published - May 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Health Policy
Fingerprint
Dive into the research topics of 'Management of papillary thyroid cancer: An overview for the primary care physician'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS